👤 Xinmei Shen

9 articles tracked

About this journalist

Articles
9
2026-08-25 – 2026-10-12
Claims per article
3
31 extracted in total
Hedged claims
23%
corpus average 9%
Typical length
898
characters
Writes for South China Morning Post.
Hedged claims are ones written with attribution or uncertainty (“reportedly”, “according to”). A higher rate is not a fault: it is often careful sourcing. How these are measured.

What they cover

Technology
56%
Health
22%
Economy/Business
11%
Politics
11%
Most-tagged topics
ChinaChineseFDAHong KongAnew LabsArriVentArriVent BioPharmaBeijing

Leaning

Not enough articles to place this byline.
1 scored article; a leaning average needs at least 8 before it says more about the writer than about which stories they happened to be assigned. Their outlet averages -0.10 (centre).

More from this journalist

Ordered by how many newsrooms covered the same event.
2026-09-18 · South China Morning Post · Economy/Business
From US Fed rates to China’s global export share: 4 figures shaping markets
21 outlets covered this event
2026-10-12 · South China Morning Post · Technology
Former HSBC executive launches wealth platform powered by team of AI agents
no other outlet in the corpus covered this
2026-10-07 · South China Morning Post · Health
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
no other outlet in the corpus covered this
2026-09-26 · South China Morning Post · Technology
China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
no other outlet in the corpus covered this
2026-09-24 · South China Morning Post · Health
US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious
no other outlet in the corpus covered this
2026-09-23 · South China Morning Post · Politics
Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
no other outlet in the corpus covered this · leans right

What they said would happen

2026-09-23 · South China Morning Post
Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
🔮 Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts speculative
2026-09-26 · South China Morning Post
China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
🔮 Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion. assertive
Forward-looking sentences extracted from their articles, oldest first. Nothing here checks whether any of it turned out to be right.
💬Give feedback
🕘History 🎫Support